Ardelyx (NASDAQ:ARDX) Reaches New 52-Week Low – Should You Sell?

Ardelyx, Inc. (NASDAQ:ARDX) hit a new 52-week low during trading on Monday. The stock traded as low as $3.28 and last traded at $3.3250, with a volume of 718706 shares. The stock had previously closed at $3.34.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Ardelyx plans to present new real-world XPHOZAH data and additional findings on hyperphosphatemia management at ASN Kidney Week 2026. The disclosures could provide investors with evidence supporting product effectiveness and future commercial adoption. Ardelyx to Present New Data on Hyperphosphatemia Management
• Neutral Sentiment: Several firms reminded shareholders that November 16, 2026 is the deadline to seek lead-plaintiff status in the federal securities lawsuit. Investors who purchased ARDX shares between January 13, 2025 and August 6, 2026 may be eligible to participate; these notices are largely promotional and do not represent new company operating results. Rosen Law Firm Ardelyx Investor Notice
• Negative Sentiment: The class action alleges Ardelyx misrepresented its ability to manage changing Medicare reimbursement conditions and payer utilization-management barriers affecting IBSRELA and XPHOZAH. Other notices cite allegedly optimistic peak-sales projections despite restrictions on patient starts. Although the claims have not been proven, the wave of litigation announcements increases legal, reputational and investor-confidence risks for Ardelyx (ARDX). Ardelyx Securities Class Action Allegations

Analysts Set New Price Targets

Several brokerages have recently issued reports on ARDX. LADENBURG THALM/SH SH initiated coverage on shares of Ardelyx in a research report on Tuesday, June 16th. They issued a “buy” rating and a $16.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Ardelyx in a research report on Friday, August 7th. Wedbush reiterated an “outperform” rating and issued a $9.00 price objective on shares of Ardelyx in a report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ardelyx in a research note on Friday, September 25th. Finally, BTIG Research reduced their target price on Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $13.90.

Ardelyx Price Performance

The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.69. The stock has a market cap of $824.82 million, a PE ratio of -15.05 and a beta of 0.68. The company has a fifty day moving average of $3.86 and a 200-day moving average of $5.14.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The firm’s revenue was up 34.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.08) earnings per share. Sell-side analysts expect that Ardelyx, Inc. will post -0.2 EPS for the current fiscal year.

Insider Buying and Selling

In other Ardelyx news, insider James Brady sold 15,136 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $58,424.96. Following the sale, the insider directly owned 245,930 shares of the company’s stock, valued at approximately $949,289.80. This represents a 5.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael Raab sold 58,574 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $226,095.64. Following the completion of the sale, the chief executive officer owned 1,619,792 shares in the company, valued at $6,252,397.12. The trade was a 3.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 126,059 shares of company stock valued at $486,588 over the last ninety days. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ardelyx

Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Ardelyx during the 2nd quarter worth about $119,874,000. Jupiter Topco LLC acquired a new position in Ardelyx in the second quarter valued at approximately $27,043,000. AIGH Capital Management LLC acquired a new position in Ardelyx in the second quarter valued at approximately $16,320,000. Bank of America Corp DE acquired a new position in Ardelyx in the second quarter valued at approximately $11,034,000. Finally, Rubric Capital Management LP purchased a new position in Ardelyx in the first quarter valued at approximately $11,147,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s products are designed to act locally in the gastrointestinal tract to address diseases involving phosphate, sodium, and other electrolytes.

Ardelyx’s primary products include XPHOZAH (tenapanor), an oral treatment approved in the United States to reduce intestinal phosphate absorption in adults with chronic kidney disease on dialysis who have hyperphosphatemia, and IBSRELA (tenapanor), an oral therapy approved for the treatment of irritable bowel syndrome with constipation in adults.